logo

For the Inventor, By the Inventor

New York, NY, United States of America

Margo P Cohen

USPTO Granted Patents = 11 

Average Co-Inventor Count = 1.3

ph-index = 6

Forward Citations = 134(Granted Patents)


Location History:

  • NY, NY (US) (1999)
  • New York, NY (US) (1993 - 2015)

Company Filing History:

goldMedal10 out of 15 
 
Exocell Inc.
 patents
silverMedal1 out of 1 
 
Glycadia Inc.
 patent

Years Active: 1993-2015

Loading Chart...
11 patents (USPTO):Explore Patents
1. 8962020 - Long-acting and controlled release formulations of 2-[(3-chlorophenyl) amino] phenylacetic acid (2015-02-24),
2. 6552077 - Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies (2003-04-22),
3. 6355680 - Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies (2002-03-12),
4. 6001875 - In vivo methods of treatment to prevent kidney dysfunction using (1999-12-14),
5. 5994401 - In Vivo Methods to reduce hypercholesterolemia and improve vascular (1999-11-30),
6. 5908925 - Genetically engineered immunoglobulins with specificity for glycated (1999-06-01),
7. 5518720 - Treatment of complications of diabetes with substances reactive with the (1996-05-21),
8. 5494791 - Monoclonal antibodies against glycated low density lipoprotein (1996-02-27),
9. 5312628 - Isolation of a soluble 42 KD pancreatic islet cell autoantigen (1994-05-17),
10. 5223392 - Monoclonal antibodies against glycated albumin, hybrid cell lines (1993-06-29),
11. 5183739 - Monoclonal antibodies specific for non-A1C glycated hemoglobin and (1993-02-02),

Title: The Innovative Contributions of Margo P. Cohen

Introduction

Margo P. Cohen, an accomplished inventor based in New York, NY, has made significant contributions to the field of pharmaceutical formulations through her innovative inventions. With a portfolio of 11 patents, her work focuses on creating new and improved drug delivery systems that enhance patient care and therapeutic outcomes.

Latest Patents

Among her most recent inventions are the long-acting and controlled-release formulations of 2-[(3-chlorophenyl) amino] phenylacetic acid. These formulations are designed to protect against gastric irritation and to slowly release the active ingredient, 23CPPA, over a period of time. This technology not only extends the release of the drug but also prevents excessively high blood concentrations, ensuring therapeutic levels are maintained after administration. Another notable invention involves albumin-binding compounds that inhibit nonenzymatic glycation, providing potential treatments for glycation-related pathologies.

Career Highlights

Throughout her career, Margo P. Cohen has been associated with noted companies such as Exocell Inc. and Glycadia Inc., where she played a vital role in developing innovative pharmaceutical solutions. She has consistently utilized her expertise to advance drug formulation technologies, making significant strides in the industry.

Collaborations

Margo has worked alongside distinguished colleagues such as Clyde W. Shearman and Rex Clements. These collaborations have fostered a creative environment that has allowed for the development of groundbreaking inventions and advancements in medical treatments.

Conclusion

Margo P. Cohen's contributions to the field of pharmaceutical innovations exemplify the impact of inventors on healthcare. With her extensive patent portfolio and collaborations, she continues to influence drug formulation strategies, ultimately enhancing patient outcomes in the medical community.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…